63
Participants
Start Date
December 31, 2003
Study Completion Date
March 31, 2005
Ziprasidone
"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
Ziprasidone
"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
Pfizer Investigational Site, Altamonte Springs
Pfizer Investigational Site, Lexington
Pfizer Investigational Site, Cleveland
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Libertyville
Pfizer Investigational Site, Las Vegas
Pfizer Investigational Site, Las Vegas
Pfizer Investigational Site, Las Vegas
Pfizer Investigational Site, San Diego
Pfizer Investigational Site, Kirkland
Pfizer Investigational Site, Kirkland
Pfizer Investigational Site, Belmont
Pfizer Investigational Site, Brighton
Pfizer Investigational Site, Turnersville
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Philadelphia
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY